Grande, Enrique
Arranz, José Á
De Santis, Maria
Bamias, Aristotelis
Kikuchi, Eiji
del Muro, Xavier Garcia
Park, Se Hoon
De Giorgi, Ugo
Alekseev, Boris
Mencinger, Marina
Izumi, Kouji
Schutz, Fabio A
Puente, Javier
Li, Jian-Ri
O'Donnell, Peter H
Kalebasty, Arash Rezazadeh
Ye, Dingwei
Mariathasan, Sanjeev
Bene-Tchaleu, FabioIa
Bernhard, Sandrine
Lee, Chooi
Davis, Ian D
Galsky, Matthew D
Funding for this research was provided by:
F. Hoffmann-La Roche
National Health and Medical Research Council
F Hoffmann-La Roche Ltd (2016274)
This article is maintained by: Elsevier
Article Title: Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(23)00540-5
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1470-2045(23)00539-9
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1470-2045(23)00633-2
Content Type: article
Copyright: © 2023 Elsevier Ltd. All rights reserved.